1. Jiang, Haiping, Yu, Dingyi, Yang, Penghui, Lu, Xiaoyan, Fan, Xiaohui. . Revealing the transcriptional heterogeneity of organ-specific metastasis in human gastric cancer using single-cell RNA Sequencing. In Clinical and translational medicine, 12, e730. doi:10.1002/ctm2.730. https://pubmed.ncbi.nlm.nih.gov/35184420/
2. Bexte, Tobias, Alzubi, Jamal, Reindl, Lisa Marie, Cathomen, Toni, Ullrich, Evelyn. 2022. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma. In Oncoimmunology, 11, 2081415. doi:10.1080/2162402X.2022.2081415. https://pubmed.ncbi.nlm.nih.gov/35694192/
3. Mac Donald, Alice, Guipouy, Delphine, Lemieux, William, Béland, Kathie, Haddad, Elie. 2023. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors. In Frontiers in immunology, 14, 1231916. doi:10.3389/fimmu.2023.1231916. https://pubmed.ncbi.nlm.nih.gov/37675109/
4. Kamiya, Takahiro, Seow, See Voon, Wong, Desmond, Robinson, Murray, Campana, Dario. 2019. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. In The Journal of clinical investigation, 129, 2094-2106. doi:10.1172/JCI123955. https://pubmed.ncbi.nlm.nih.gov/30860984/
5. Shankar, Keerthana, Zingler-Hoslet, Isabella, Shi, Lei, Capitini, Christian M, Saha, Krishanu. 2024. Virus-free CRISPR knock-in of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells. In bioRxiv : the preprint server for biology, , . doi:10.1101/2024.02.14.580371. https://pubmed.ncbi.nlm.nih.gov/38405747/
6. Shreeve, Norman, Depierreux, Delphine, Hawkes, Delia, Sharkey, Andrew M, Colucci, Francesco. 2021. The CD94/NKG2A inhibitory receptor educates uterine NK cells to optimize pregnancy outcomes in humans and mice. In Immunity, 54, 1231-1244.e4. doi:10.1016/j.immuni.2021.03.021. https://pubmed.ncbi.nlm.nih.gov/33887202/
7. Bexte, Tobias, Albinger, Nawid, Al Ajami, Ahmad, Imkeller, Katharina, Ullrich, Evelyn. 2024. CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. In Nature communications, 15, 8439. doi:10.1038/s41467-024-52388-1. https://pubmed.ncbi.nlm.nih.gov/39349459/
8. Hussein, Brwa Ali, Kristenson, Linnea, Pesce, Silvia, Bernson, Elin, Thorén, Fredrik B. . NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells. In Journal for immunotherapy of cancer, 11, . doi:10.1136/jitc-2023-007202. https://pubmed.ncbi.nlm.nih.gov/37648262/
智鼠故事 
